Tag: arrhythmia

Advances in the Application of Pulsed Field Ablation for Arrhythmia Treatment

Announcing a new article publication for Cardiovascular Innovations and Applications journal. The increased application of catheter ablation to treat cardiac arrhythmias has contributed to continued exploration of safe and effective tissue ablation tools in the field of electrophysiology. Pulsed field ablation (PFA), a novel recently developed non-thermal energy-based technique, uses trains of microsecond duration high-amplitude pulses to ablate target cells. Several preclinical and clinical studies have demonstrated that PFA is a promising tool for cardiac ablation to treat arrhythmia. In addition to being an effective tissue ablation technique, PFA is safe, because it avoids damage to the surrounding cells/tissues. This article focuses on efficacy and safety outcomes reported in preclinical and clinical studies evaluating the effects of PFA on arrhythmia, and discusses limitations and potential future directions of PFA.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0019

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Fuding Guo, Jun Wang and Liping Zhou et al. Advances in the Application of Pulsed Field Ablation for Arrhythmia Treatment. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0019

Loading

Renal Denervation: Past, Present, and Future

Renal Denervation: Past, Present, and Future

Authors: Pourafshar, Negiin; Karimi, Ashkan; Anderson, R. David; Alaei-Andabili, Seyed Hossein; Kandzari, David E.

Over the past decade, percutaneous renal denervation has been vigorously investigated as a treatment for resistant hypertension. The SYMPLICITY radiofrequency catheter system (Medtronic CardioVascular Inc., Santa Rosa, CA, USA) is the most tested device in clinical trials. After the positive results of small phase I and II clinical trials, SYMPLICITY HTN-3 (a phase III, multi-center, blinded, sham-controlled randomized clinical trial) was completed in 2014, but did not show significant blood pressure lowering effect with renal denervation compared to medical therapy and caused the investigators and industry to revisit both the basic science elements of renal denervation as well as the design of related clinical trials. This review summarizes the SYMPLICITY trials, analyzes the SYMPLICITY HTN-3 data, and provides insights gained from this trial in the design of the most recent clinical trial, the SPYRAL HTN Global clinical trial. Other than hypertension, the role of renal denervation in the management of other disease processes such as systolic and diastolic heart failure, metabolic syndrome, arrhythmia, and obstructive sleep apnea with the common pathophysiologic pathway of sympathetic overactivity is also discussed.

DOI: http://dx.doi.org/10.15212/CVIA.2016.0016

Loading